Loading
Life sciences · Journal article
Acs Applied Bio Materials · October 3, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Chondroitin sulfate (CS), a sulfated glycosaminoglycan, has attracted considerable attention in nanomedicine owing to its excellent biocompatibility, biodegradability, and intrinsic bioactivity. Recent advances in CS-based nanoplatforms, including nanogels, nanoparticles, hydrogels, and other drug delivery systems, have enabled targeted drug delivery, tissue engineering, and regenerative medicine applications. These multifunctional systems facilitate controlled drug release, enhance cellular uptake, and regulate key biological processes such as inflammation, oxidative stress, and extracellular matrix remodeling. Beyond their roles in material design, CS-based nanoplatforms have demonstrated promising preclinical potential in cancer therapy, osteoarthritis, periodontitis, cartilage regeneration, wound healing, ophthalmic disorders, liver fibrosis, and neurodegenerative diseases. This review first discusses the design principles and functional characteristics of CS-based material platforms followed by their therapeutic applications in tissue engineering and disease treatment. Finally, the current challenges, translational perspectives, and future opportunities for the clinical development of CS-based nanoplatforms are highlighted.